DENVER, CO--(Marketwired - Dec 31, 2013) - MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, today announced that it has retained PondelWilkinson Inc. as investor relations counsel.
The firm will serve as liaison for MusclePharm to the investment community, as well as provide counsel for strategic communications as MusclePharm embarks on its next stage of growth and development.
"The engagement of PondelWilkinson represents a timely step for MusclePharm, as we continue to build our company, forge new relationships with shareholders and the broader investment community, and look toward listing our shares on a senior exchange," said Brad Pyatt, MusclePharm's president and CEO. "Our decision was based on the firm's expertise in the consumer sector, as well as its experience over many years representing high profile growth companies."
"We are delighted to join forces at this important stage in the company's growth, helping to build further brand awareness in the corporate and investor communities for MusclePharm's distinctive leadership niche in the sports nutrition sector," said Roger Pondel, CEO of PondelWilkinson.
PondelWilkinson Inc., founded in 1968, provides investor relations and strategic public relations counsel to publicly traded, pre-public and privately owned companies in various industries, as well as marketing communications support for professional and financial services firms. View PondelWilkinson's website at www.pondel.com, and its blog at www.pwinsight.com.
MusclePharm® is a leading international, award-winning sports nutrition company offering vitamins and nutritional supplements which are available in more than 110 countries and available in 35,000+ retail outlets, including Costco, Dick's Sporting Goods, 24 Hour Fitness, Bally's, GNC, Vitamin Shoppe and Vitamin World. The company's brands are MusclePharm®, Arnold Schwarzenegger™ Series, and FitMiss™. The comprehensive lines of clinically-proven, safe and effective nutritional supplements are developed through a six-stage research process that utilizes the expertise of leading nutritional scientists, doctors and universities. For more information, visit www.musclepharmcorp.com. Follow the company at http://www.facebook.com/MusclePharm and www.Twitter.com/MusclePharm.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the company's business. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the company's Quarter Reports on Form 10-Q and other filings submitted by the company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.